Leading medical AI company YIDU TECH (02158) has recently won two significant project bids, demonstrating its dual core competencies in both public health and specialized oncology AI. On the 15th, Northeast Securities Co.,Ltd. issued a research report assigning the company an "Add" rating, expressing optimism about the acceleration of its AI solutions' commercialization and the continued advancement of its internationalization strategy.
The company, through its affiliate Yidu Cloud (Beijing) Technology Co., Ltd., secured two key contracts according to announcements on April 8th and 13th. The first is an AI development project for a "bank-hospital cooperation" initiative with Beijing Cancer Hospital, valued at approximately 4.88 million yuan, highlighting the company's deep integration into the specialized oncology AI field. The second is the Hainan Provincial Integrated Regional Infectious Disease Monitoring, Early Warning, and Emergency Command Information Platform (Phase II) project, with a total value of around 12.89 million yuan, showcasing YIDU TECH's core capabilities in the digital transformation of public health emergency management systems.
Northeast Securities Co.,Ltd. noted that the successful acquisition of these two projects indicates the growing competitiveness of the company's "AI Medical Brain," YiduCore, in vertical sectors, receiving high recognition from both government and hospital clients. Furthermore, the bank-hospital cooperation model is seen as pioneering an innovative path for the commercialization of AI medical services.
YIDU TECH's international strategy is also gaining traction, with recent visits from the Health Ministers of Brunei and Indonesia to its headquarters. Important collaborative agreements were reached concerning AI upgrades for the BruHealth platform, the development of smart hospitals, and the intelligent transformation of national health data platforms. Northeast Securities Co.,Ltd. believes the company's international expansion is accelerating, potentially unlocking a second growth curve and effectively diversifying risks associated with a single market.
Currently, YIDU TECH has established a comprehensive "hospital-pharmacy-insurance-patient" ecosystem, serving over 10,000 medical institutions. Notably, 17 out of the top 20 multinational pharmaceutical companies are its clients.
The company is persistently executing its three core strategies: large-scale deployment of its intelligent agent ecosystem, deepening disease research and applications, and advancing human-AI collaborative services, leading to steady improvements in operational efficiency. As of September 30, 2025, the company's total cash, cash equivalents, and term deposits amounted to 2.1 billion yuan, providing a solid foundation for ongoing AI R&D and international expansion.
Northeast Securities Co.,Ltd. anticipates that with an increasing proportion of high-margin business and the realization of economies of scale, YIDU TECH is well-positioned to achieve breakeven profitability and enter a new phase of high-quality development.